ClinicalTrials.gg
Active, not recruitingNCT05483530Updated Apr 16, 2024

A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of HLX60 combined with HLX10 in Advanced or Metastatic Solid Tumors, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety and tolerability of HLX60 combined with HLX10 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.

Read the detailed description

Accelerated titration and "3 + 3" dose escalation were used in this trial . various doses of HLX60(anti-GARP) combined with HLX10(anti-PD-1) by intravenous infusion.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically confirmed advanced malignant solid tumor, who have failed or cannot receive the standard treatment;
  • With at least one evaluable lesion according to v1.1 (for solid tumors);
  • Patients must be able to supply adequate tumor tissue for biomarker (including the expression of , GARP) analyses;
  • longer than three months;
  • Participant has an (ECOG) Performance Status of 0 to 1.

Exclusion criteria

Exclusion Criteria:

  • Has a concurrently active second , other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. Participants with history of the second malignancy have been disease-free for \<3 years.
  • Has a history of (non-infectious) interstitial lung disease (ILD) that required , currently has ILD, or when suspected ILD cannot be ruled out by imaging at screening.
  • Participant has unresolved AEs ≥ Grade 2 from prior anticancer therapy except for alopecia.
  • Those who have received anti-GARP or anti-GARP/TGFβ complex antibody therapy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    HLX60 combined with HLX10

    Biological: HLX60 combined with HLX10

Interventions

  • BiologicalHLX60 combined with HLX10

    Drug page: Serplulimab

    five various doses of HLX60 combined with flat dose of HLX10

06

What researchers measure

Primary outcomes

  1. Adverse event

    Incidence and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 for patients receiving study drug.

    Time frame: Through study completion, assessed up to 2 years.

  2. Incidence of DLT

    Ratio of the number of patients with DLT events in each dose group to the number of patients in the dose group during the DLT evaluation period.

    Time frame: Up to 3 weeks.

  3. MTD

    The maximum tolerated dose (MTD) of HLX60 combined with HLX10

    Time frame: Up to 3 weeks.

  4. RP2D

    The recommended phase II dose (RP2D) of HLX60 combined with HLX10

    Time frame: Through study completion, assessed up to 2 years.

Secondary outcomes

  1. Objective response rate (ORR)

    Percentage of patients with complete response or partial response determined by investigators according to RECIST v1.1

    Time frame: Through study completion, assessed up to 2 years.

  2. Progression-free survival (PFS)

    PFS is defined as the time from the first administration of HLX60 and HLX10 to the first occurrence of disease progression or death due to any cause, whichever occurs first.

    Time frame: Through study completion, assessed up to 2 years.

  3. Overall survival(OS)

    OS is defined as the time from the first administration of HLX60 to death due to any cause.

    Time frame: Through study completion, assessed up to 2 years.

  4. Cmax

    serum concentration (Cmax)

    Time frame: 1 year

  5. Tmax

    time to reach Cmax (Tmax)

    Time frame: 1 year

  6. t1/2

    elimination half-life (t1/2)

    Time frame: 1 year

  7. AUC

    area under the serum concentration-time curve (AUC)

    Time frame: 1 year

  8. PD

    include the GARP receptor occupancy on Treg cells, tumor infiltrating lymphocytes (TILs), FOXP3, pSMAD 2/3 in tumor tissues.

    Time frame: 1 year

  9. immunogenicity of HLX60

    Incidence of HLX60 anti-drug antibody (ADA) and neutralizing antibody (NAb)

    Time frame: 1 year

  10. Potential prognostic and predictive biomarkers

    include the expressions of GARP, PD-L1 in tumor tissues and soluble GARP in peripheral blood.

    Time frame: 1 year

07

Study locations

1 site
  • Macquarie University Hospital & Nepean Hospital
    Sydney, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Aug 2, 2022
StartActual
Dec 14, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Aug 2025
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05483530
Responsible party
Sponsor
First posted
Aug 2, 2022
Start date
Dec 14, 2022
Primary completion
Dec 2024 (estimated)
Completion
Aug 2025 (estimated)
Last update
Apr 16, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion